

**Information notice on
the conclusion of a related party agreement
pursuant to article L. 22-10-13 of the French Commercial Code**

Communication and know-how transfer agreement
(Authorized by the Board of Directors on December 15, 2023)

Daix, Mai 30, 2024 - Pursuant to Articles L. 22-10-13 and R 22-10-17 of the French Commercial Code, Inventiva S.A. (the "Company") points out that on December 20, 2023 it signed a communication and know-how transfer agreement with Mr. Pierre BROQUA.

Purpose: As part of the verification of the regularity of the Company's rights to the patents protecting lanifibranor, the Company has documented the communication and know-how transfer agreement which provides it with a complete and regular chain of ownership of its intellectual property rights relating to the patents protecting lanifibranor.

Financial conditions: The agreement entails the following payments to Mr. Pierre BROQUA:

- € 50,000 upon signature of the agreement (subject to and after this payment being authorized by the Annual General Meeting of June 20, 2024), and
- € 50,000 if and when the first of the following events occurs:
 - (i) the granting of a marketing authorization by the health authorities of the United States of America and/or the European Union for a product whose compound, indication or manufacturing process is covered by one or more patents covered by the agreement, or
 - (ii) the signature by the Company and a third party of a licensing agreement covering one or more of the patents covered by the agreement, with the geographical territory being the United States of America and/or the European Union.

There will be only one additional payment if the above condition is met.

It is agreed that the above sums of € 50,000 are net of all taxes and other compulsory levies to which Mr. Pierre BROQUA is subject. To date, in accordance with applicable regulations, this represents:

- (i) an additional expense of €18,681.32, and, therefore,
- (ii) the payment to Mr. Pierre BROQUA of €50,000 under this agreement represents a total cost to the Company of €68,681.32.

Person concerned: Mr. Pierre BROQUA, Deputy Chief Executive Officer of the Company, Director of the Company and shareholder with more than 10% of voting rights in the Company.

Reasons why it is in the Company's interest to enter into the Agreement: Entering into the agreement enables the Company to satisfy the need to justify a complete and regular chain of title to its intellectual property rights relating to the patents protecting lanifibranor.

Agreement approval procedures: The Company's Board of Directors authorized the signature of the agreement at its meeting of December 15th, 2023, in accordance with article L. 225-38 of the French Commercial Code. Mr. Pierre BROQUA did not take part in the deliberations or vote. The conclusion of the agreement will be submitted for ratification to the next General Meeting of the Company's shareholders.

* * *